By: Debbie Hart, president and CEO, BioNJ
How many times did you hear, “Here’s to good health” this holiday season? As we age, we become increasingly aware of the importance of “good health.” That’s one reason so many people felt hopeful about a recent announcement by the Food and Drug Administration (FDA) that the agency approved more than 50 new molecular entities in 2018, including 16 approvals for cancer drugs, as well as drugs for HIV, Hepatitis C and rare diseases. Twenty of the new drugs came from companies with a footprint in New Jersey. More here.